Compare TSLX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | FTRE |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2011 | 2023 |
| Metric | TSLX | FTRE |
|---|---|---|
| Price | $17.53 | $9.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $21.72 | $15.39 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.92 | $3.01 |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $16.99 | $3.97 |
| 52 Week High | $25.17 | $18.67 |
| Indicator | TSLX | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 35.46 |
| Support Level | $17.15 | $8.85 |
| Resistance Level | $18.57 | $11.22 |
| Average True Range (ATR) | 0.46 | 0.57 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 15.12 | 26.11 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.